-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2891 Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster II
Hematology Disease Topics & Pathways:
Research, Clinical trials, Acute Myeloid Malignancies, AML, Combination therapy, Adult, Clinical Research, Diseases, Treatment Considerations, Myeloid Malignancies, Study Population, Human, Measurable Residual Disease
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Giovanni Marconi, MD1,2, Alfonso Piciocchi3*, Ernesta Audisio, MD4*, Cristina Papayannidis, MD, PhD5, Fabio Guolo, MD, PhD6,7, Marco Cerrano, MD8*, Valentina Arena3*, Saveria Capria, MD9*, Michela Rondoni10*, Matteo Giovanni Della Porta, MD11*, Germana Beltrami, MD12*, Monica Bocchia, MD13*, Albana Lico14*, Luisa Giaccone, MD, PhD15*, Marianna Rossi, MD16*, Catello Califano17*, Matteo Giovanni Carrabba, MD18*, Chiara Cattaneo, MD19, Marco Frigeni20*, Maria Chiara Di Chio21*, Bianca Serio, MD22*, Roberto Freilone, MD23*, Antonio Curti, MD, PhD5, Paola Minetto, MD24, Giovanni Marsili3*, Clara Minotti25*, Beatrice Anna Zannetti26*, Francesca Cotugno27*, Jacopo Nanni, MD28*, Giorgia Simonetti, Ph.D.29*, Maria Teresa Bochicchio30*, Sara Rosellini31*, Elisabetta Tedone7*, Adriano Venditti32, Roberto Massimo Lemoli, MD33,34*, Marco Vignetti, MD3*, Paola Fazi3* and Giovanni Martinelli, M.D.35,36

1Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l., Meldola, Italy
2Ospedale S. Maria delle Croci, university of Bologna, Bologna, Italy
3GIMEMA Foundation, Rome, Italy
4SC EMATOLOGIA 2, AOU CITTA DELLA SALUTE E DELLA SCIENZA, OSPEDALE S. GIOVANNI BATTISTA MOLINETTE, Torino, ITA
5IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
6Hematology Unit, Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy
7IRCCS Ospedale Policlinico San Martino, Genoa, Italy
8Division of Hematology, Department of Oncology, A.O.U. Città della Salute e della Scienza di Torino, Torino, To, Italy
9Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
10Hematology Unit & Metropolitan Transplant Network, AUSL Romagna, Ravenna, Italy
11Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy
12U.O. Ematologia e terapie cellulari, IRCCS Azienda Ospedaliera Universitaria San Martino, Genova, Italy
13Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy
14Hematology Unit, Hematology Unit, San Bortolo Hospital, Vicenza, Italy, Vicenza, Italy
15Univesity of Torino, AOU Città Della Salute E Della Scienza Di Torino,, Torino, ITA
16Division of Hematology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy, Pavia, ITA
17Unità Operativa Complessa di Onco-Ematologia del Plesso Ospedaliero “Andrea Tortora” di Pagani, Nocera Inferiore, ITA
18Hematology and Bone Marrow Transplantation Unit, I.R.C.C.S. San Raffaele Scientific Institute, Milan, Italy
19Hematology, ASST Spedali Civili, Brescia, Italy
20Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy
21Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
22Department of Medicine and Surgery, University of Salerno, University of Salerno, Baronissi, Salerno, Italy
23Hematology, Department of Hematology and Oncology, Città della Salute e della Scienza di Torino, Torino, Italy
24Clinic of hematology, Department of Internal medicine (DiMI), University of Genoa, Genova, Italy
25Department of Translational and Precision Medicine, Division of Hematology, Sapienza University, Rome, Italy
26Hematology Unit & Metropolitan Transplant Network, Ravenna and Stem Cell Transplant, AUSL Romagna, Ravenna, Italy
27Fondazione Gimema, Roma, Italy
28Department of Medical and Surgical Sciences - University of Bologna, Bologna, Italy
29IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori", Meldola, Italy
30IRCSS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l, Meldola, Italy
31Servizio di Citofluorimetria, Dipartimento di Anatomia Patologica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
32Department of Onco-Hematology, Fondazione Policlinico Tor Vergata, Rome, Italy
33Clinic of Hematology, Department of Internal medicine (DiMI), University of Genoa, Genoa, Italy
34Clinic of Hematology, University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Genoa, Italy
35Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy
36IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy

Background: Prognosis of intermediate and high-risk acute myeloid leukemia (AML) remains poor, with a 2-year estimated overall survival of about 30-40% in the young population. AML1718 trial combined venetoclax with fludarabine, idarubicine, and cytarabine (V-FLAI) with the specific aim of improving cure rate of these AML patients. Primary end-point analysis of the AML1718 trial demonstrated remarkable efficacy in term of probability of complete remission (CR) and mesurable residual disease negativity (MRD), 79% and 64%, respectively. Hereby, we present the mature data with overall survival and disease free survival analysis of the study.

Methods: The GIMEMA AML1718 phase 1/2 multicenter trial (NCT03455504) enrolled patients from Feb 2019 to Feb 2023 and investigated safety and efficacy of V-FLAI as a first-line treatment for newly diagnosed adult patients with ELN 2017 intermediate- or high-risk AML. The study followed a modified two-stage Simon's design; safety of the combination of venetoclax 400 or 600 mg and FLAI was established in a safety run-in (6+6 patients); the two different dosages of venetoclax were randomly compared in part 1, with no significant difference (22+23 patients). Part 2 consisted in a confirmatory cohort of 67 patients treated at the lower effective dosage, as predefined (V-FLAI 400 mg). A second inductin was possible for patients without complete remission (CR/Cri/CRh). In patients responding to single induction, cytarabine-based consolidation were administered based on center guidelines. VEN administration was discontinued until recovery for patients achieving remission by day 21 and during consolidation courses; predefined dose adjustments were planned for patients receiving posaconazole. Allogeneic hematopoietic stem cell transplant (HSCT) was indicated as soon as possible. In part 2, a centralized MRD assessment was performed. Baseline characterization of patients with 91-genes panel is ongoing, and will eventually be presented at the meeting.

Results: Mature follow-up data are available for all the 124 consecutive patients who received V-FLAI in the study. As previously reported, the median age was 55 years (ranging from 18 to 66), with 70 patients (56%) being male. The vast majority of the patients were of European ancestry. All the patient had baseline ECOG performance status <2. At baseline, 67 patients (54%) were locally classified as intermediate risk and 57 patients (46%) as high-risk, mostly basing on cytogenetic analysis, NPM1 and FLT3 status; the classification will be updated basing on centralized genetic analysis. FLT3 mutation was positive in 19 patients (15.3%), NPM1 mutation in 3 patients (2.4%), while 17 patients (14%) had a seconday AML.

In our set, 95 patients received V-FLAI 400 mg and 29 patients V-FLAI 600 mg. After induction, 74 patients (59.6%) proceded to consolidation and 71 received HSCT (57.2%, of which 63, 93% in 1st CR). With a median follow-up of 22 months (IQR 11 – 31) , 1- and 2- years overall survival were 61% (95% CI 53-71) and 48% (95% CI 38-59) while 1- and 2- years disease free survival were 60% (95% CI 50-72) and 46% (95% CI 35%-60%), respectively. After 2 years, death and relapse probability lowered, and shape of the curves seems to suggest a plateau. Central MRD proven predictive value on disease free survival, results will be detailed presented in a separate abstract.

As far as safety is of concern, we confirmed the low-incidence of treatment-related mortality, with 5 deaths recorded during induction (4.0%, no difference according VEN dose), a safety profile comparable with other intensive inductions regiments and no instances of graft failure or higher-than-expected incidence of graft-versus-host disease. No severe late effect of the combination was reported up to now.

Conclusions: V-FLAI efficacy translated in long term survival for most of the treated patients. No unexpected long term toxicity or transplant-related toxicity emerged. Predicted 2 years survival seems to favor the adoption of this combination over other alternatives in the non-low-risk, fit population; a randomized trial comparison with the standard of care is warranted.

Disclosures: Marconi: UKNEQUAS: Speakers Bureau; Takeda: Speakers Bureau; Syros: Consultancy, Membership on an entity's Board of Directors or advisory committees; Servier: Speakers Bureau; Ryvu: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Menarini/Stemline: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Jansenn: Speakers Bureau; Immunogen: Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Research Funding; Astrazeneca: Research Funding, Speakers Bureau; Astellas: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Consultancy, Research Funding, Speakers Bureau. Papayannidis: Servier: Honoraria; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria; Menarini/Stemline: Honoraria; BMS: Honoraria; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees; Blueprint: Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Delbert Laboratories: Membership on an entity's Board of Directors or advisory committees. Cerrano: Jazz: Other: Educational activity ; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees; Servier: Honoraria, Other: Educational activity ; Italfarmaco: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astellas: Other: Educational activity ; Abbvie: Honoraria, Other: Educational activity ; Janssen: Other: Educational activity ; Otsuka: Other: Educational activity ; Pfizer: Other: travel support. Bocchia: Novartis: Honoraria, Other: travel grant; Incyte: Honoraria, Other: travel grant; Abbvie: Honoraria, Other: travel grants. Giaccone: Abbvie: Honoraria. Cattaneo: Pfizer: Other: travel grant; JANSSEN: Other: travel grant; Jazz: Other: travel grant. Curti: Abbvie: Honoraria; Menarini stemline: Honoraria; Jazz Pharmaceutics: Honoraria; Pfizer: Honoraria, Research Funding. Venditti: servier: Consultancy, Other: invited speaker; astellas: Consultancy, Other: invited speaker; AstraZeneca: Consultancy; Gilead: Consultancy, Other: invited speaker; beigene: Consultancy; menarini: Consultancy, Other: invited speaker; Abbvie: Consultancy, Other: invited speaker; glycostem: Consultancy; BMs celgene: Consultancy, Other: invited speaker; jazz: Consultancy, Other: invited speaker, Research Funding; Janssen: Consultancy, Other: invited speaker; pfizer: Consultancy, Other: invited speaker; laboratories Delbert: Consultancy; istituto gentili: Consultancy. Lemoli: Jazz Pharma: Speakers Bureau. Vignetti: Vertex: Honoraria; Edrea: Honoraria; Mattioli Health: Honoraria; Arhea: Honoraria; Isheo: Honoraria; Novartis: Honoraria; Astrazeneca: Honoraria; Abbvie: Honoraria; Dephaforum SRL: Honoraria. Martinelli: MSD: Consultancy; ARIAD: Consultancy; Bristol Myers Squibb (BMS): Consultancy; Novartis: Consultancy; Roche: Consultancy; Pfizer: Research Funding.

OffLabel Disclosure: Venetoclax is combined with chemotherapy off-label

*signifies non-member of ASH